SCHEMBL17066201

SCHEMBL17066201

CC(C)c1cnn(-c2ccccc2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
BCHE P06276 1/20 0.41
MTOR P42345 1/20 0.40
NOTUM Q6P988 1/20 0.40
PTGS2 P35354 1/20 0.36
PARP1 P09874 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
PKM P14618 1/20 0.34
MGLL Q99685 1/20 0.33
AVPR2 P30518 1/20 0.33
AVPR1A P37288 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
CNR1 P21554 1/20 0.33
NPBWR1 P48145 1/20 0.33
MCHR1 Q99705 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2609436 0.84 RXRA (0.44) ALDH1A1LMNASMN1; SMN2NOTUMDRD3
SCHEMBL9130757 0.83 BCHE (0.38) ALDH1A1LMNASMN1; SMN2BCHEMTOR
SCHEMBL18254780 0.81 RXRA (0.40) ALDH1A1LMNASMN1; SMN2ADORA3PKM
SCHEMBL17066200 0.81 NOTUM (0.42) LMNASMN1; SMN2NOTUMPKMCNR1
SCHEMBL21775967 0.80 HPGD (0.39) ALDH1A1SMN1; SMN2EGLN1DRD3IRAK4
SCHEMBL18878391 0.80 GRM4 (0.45) MTORNOTUMADORA3DRD4DRD3
SCHEMBL14328381 0.78 DRD2 (0.44) ALDH1A1LMNAMTORMGLLDRD4
SCHEMBL9131851 0.77 TDO2 (0.46) ALDH1A1SMN1; SMN2BCHEMTORNOTUM
SCHEMBL6271350 0.77 BCHE (0.46) LMNASMN1; SMN2BCHEMTORNOTUM
SCHEMBL21706148 0.76 CREBBP (0.41) ALDH1A1SMN1; SMN2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-11-05 US disclosed
US-10640500-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-05-05 US disclosed
US-9850242-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD (JP) 2017-12-26 US disclosed
US-9850242-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD (JP) 2017-12-26 US disclosed
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-11-24 US disclosed
US-9446046-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-20 US disclosed
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-02-04 US disclosed
US-9126999-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640500-B2 Tetrahydropyrazolopyrimidine compounds SSB, TLR8, TLR9 ALDH1A1 3879/4885LMNA 2638/4885SMN1; SMN2 4689/4885
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 ALDH1A1 3834/4885LMNA 2245/4885SMN1; SMN2 4635/4885
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 ALDH1A1 3834/4885LMNA 2245/4885SMN1; SMN2 4635/4885
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 ALDH1A1 3879/4885LMNA 2638/4885SMN1; SMN2 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.